Author
Founder and Editor
Tristen Ta is the founder and editor of PeptidesInfo, an independent publication that examines peptide research, regulatory status, evidence quality, and emerging applications for a general audience.
Not a licensed clinician; does not provide medical review.
Retatrutide is the next-generation weight-loss drug that hits three hormone targets at once. Trial results are striking, but it is not FDA-approved and cannot be legally compounded. Here is what the evidence actually shows.
Copper peptides and biotinoyl tripeptide-1 are sold widely for hair loss. The supporting studies are mostly cells and animals. Here is what exists in humans, and how it compares with the two treatments that have decades of trial data.
Better sleep and more energy are standard peptide selling points. No growth-hormone secretagogue has been tested with sleep laboratory measurement, and the one peptide with a large sleep trial works by a completely different route.
Copper peptides and topical retinoids are both sold for photoaged skin. One has several small trials, the other decades of large ones. What each has actually demonstrated, and the head-to-head trial nobody has run.
"FDA-approved" and "works" are different questions, and conflating them is how most peptide confusion starts. This explains the two independent axes — regulatory status and evidence level — with four worked examples.
Fake and counterfeit versions of semaglutide and tirzepatide are being sold online, sometimes with made-up pharmacy labels. Here is how the FDA says to recognize them and buy safely.
Compounded semaglutide is not the same as Ozempic or Wegovy. It is not FDA-checked, the shortage that made it common is over, and the FDA has linked it to dosing errors and hospital visits. Here is the plain version.
Growth-hormone peptides are sold almost entirely on muscle claims. No controlled trial has measured muscle with them. The one peptide with positive lean-mass data is the one nobody markets for it.
Appetite changes in weeks, weight declines for over a year before plateauing, and cardiovascular benefit separates over months. Here is when each GLP-1 benefit appeared in the trials that measured it.
Whether a peptide is worth it depends on four things: what benefit is proven, in whom, for how long, and whether the effect lasts after you stop. Here is that framework applied to every peptide we cover.
Two peptides produce large, well-documented weight loss in randomised trials. Several others are marketed for fat loss with no outcome data at all. Here are the numbers, the timeframes, and what happens when you stop.
Skin is one of the few areas where peptides have real human trials. Topical copper peptides and oral collagen both improve measurable skin properties — modestly, over weeks, in studies mostly funded by the people selling them.
Recovery is the most-marketed peptide benefit and the least proven. This separates the recovery claims with human trials behind them from the ones resting entirely on rodent studies — and names what would change the verdict.
Peptides are credited with dozens of benefits. Some are proven in large trials, some are modest and real, and some have never been tested in a person. This is every major benefit claim, sorted by how strong the human evidence is.
Semaglutide and tirzepatide have now shown benefits in cardiovascular events, kidney disease, liver disease, heart failure and sleep apnoea — each in its own trial, in its own population. Here is what each one actually demonstrated.
Collagen peptides have more randomised human trials than any other supplement peptide. The benefits are real, small, and take 8–24 weeks to appear. Here is what each one is worth in measurable terms.
Semaglutide and tirzepatide are the best-evidenced peptides in medicine — for specific uses. We separate the approved indications with large trials from the emerging research (kidney, liver, heart failure, sleep apnoea, Alzheimer's) and the open questions about regain, muscle loss and compounded products.
BPC-157 has hundreds of positive animal studies and almost no controlled human data. We separate what the rat research shows, what the few human reports show, what the FDA has said, and what would have to happen for the evidence grade to change.
A certificate of analysis is the main reassurance offered by 'research peptide' vendors. Here is what a CoA can and cannot tell you — identity, purity, quantity, sterility, endotoxin — why '99% pure' is not what it sounds like, and what independent testing of grey-market peptides has found.
The 'CJC/ipa' stack is sold for muscle, fat loss, sleep and anti-aging. The human evidence is a handful of short hormone-level studies, two abandoned development programmes, and no outcome trials — plus a set of risks that have never been studied because the trials were never run.
Tesamorelin is the one GHRH analogue that finished phase 3 and won FDA approval — for excess abdominal fat in HIV-associated lipodystrophy. We separate that established evidence from the off-label uses it is now marketed for: general visceral fat, liver fat, and cognition.
TB-500 is sold on the back of thymosin beta-4 research — a different molecule with real but early human trials in wounds and eye disease. We untangle which studies are about what, and what that means for the fragment people actually buy.
PT-141 (bremelanotide) is FDA-approved as Vyleesi for low sexual desire in premenopausal women, with modest benefits and a lot of nausea. Its use in men — the way it is mostly marketed online — was abandoned in development. Here is what the trials actually showed.
Copper peptide GHK-Cu has decades of laboratory work, small human trials for topical skin use, and a growing injectable market with no human data. We grade each claim — skin, hair, wounds, 'gene resetting' — separately.
Oral collagen peptides are the rare non-drug peptide product with multiple randomised trials. The effects on skin hydration, activity-related joint pain and (with training) lean mass are real but small, and most trials are industry-funded. Here is what the studies show and where the gaps are.
The regulatory status of a peptide is a fact about a decision, not a verdict on the evidence. This guide explains the four categories, what compounding rules changed in 2023–2025, and where every peptide we cover currently sits.
Most misleading peptide claims cite real studies. This guide shows how to tell a rat model from a human trial, a mechanism from an outcome, and a case report from evidence — with worked examples from BPC-157, growth hormone secretagogues and collagen research.
Peptides are short chains of amino acids that range from approved blockbuster drugs to unregulated 'research chemicals'. Here is what the word actually covers, how peptides differ from proteins and small-molecule drugs, and why the category tells you nothing about evidence.
